Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study

被引:25
作者
Lu, Linbin [1 ]
Shen, Lujun [2 ]
Wu, Zhixian [3 ]
Shi, Yanhong [4 ]
Hou, Peifeng [5 ]
Xue, Zengfu [6 ]
Lin, Cheng [7 ,8 ]
Chen, Xiong [1 ]
机构
[1] Fujian Med Univ, Hosp 900, Dept Oncol, Joint Logist Support Force,PLA,Fuzong Clin Coll, 156 Xierhuan Northern Rd, Fuzhou 350025, Fujian, Peoples R China
[2] Sun Yat Sen Univ, Dept Minimally Invas Intervent Therapy, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China
[3] Xiamen Univ, Dept Hepatobiliary Dis, Med Coll, Dongfang Hosp, Fuzhou 350025, Fujian, Peoples R China
[4] Fujian Med Univ, Dept Oncol, Mengchao Hepatobiliary Hosp, Fuzhou 350025, Fujian, Peoples R China
[5] Fujian Med Univ, Dept Oncol, Union Hosp, Fuzhou 350001, Fujian, Peoples R China
[6] Xiamen Univ, Dept Digest Dis, Affiliated Hosp 1, Xiamen 361003, Fujian, Peoples R China
[7] Fujian Med Univ, Dept Radiotherapy, Canc Hosp, Fuzhou 350014, Fujian, Peoples R China
[8] Fujian Canc Hosp, Fuzhou 350014, Fujian, Peoples R China
关键词
Hepatocellular carcinoma; Transarterial chemoembolization; AFP trajectory; AFP serological response; Hit-differentiation hypothesis; RESPONSE PREDICTS SURVIVAL; LIVER-TRANSPLANTATION; DOUBLE-BLIND; SORAFENIB; BENEFITS; THERAPY; PLACEBO;
D O I
10.1016/j.eclinm.2022.101391
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background alpha-fetoprotein (AFP) response has been proven a key tumor marker for hepatocellular carcinoma (HCC), but its definition remains controversial. This study aims to characterize AFP trajectories after transarterial chemoembolization (TACE) and examine its impact on clinical outcomes. Methods This longitudinal, multicenter, retrospective, cohort study examined data from the electronic medical record system of four hospitals in China between January 1, 2007 to December 31, 2016. A latent class growth mixed model was applied to distinguish potential AFP dynamic changing trajectories. The multivariable Cox models were used to calculate adjusted hazard ratios (aHRs) and 95% CIs for overall survival. Inverse-probability-of-treatment weighted analyses were performed to eliminate unmeasured confounders through marginal structural models. Findings A total of 881 patients, who had intermediate-stage HCC with AFP repeatedly measured 3 to 10 times, were included in the study. Three distinct trajectories were identified using the latent class growth mixture model: high-rising (25.7%; n = 226), low-stable (58.7%; n = 517), and sharp-falling (AFP serological response, 15.6%; n = 138). Compared with the low-stable class, the aHRs for death were 5.13 (3.71, 7.10) and 0.52 (0.33, 0.81) for the high-rising and sharp-falling class, adjusted by gender, baseline major tumor size, intrahepatic lesions number, and logAFP (smooth). Furthermore, high-rising class had a significantly higher HR in the subgroup of female patients (10.60, 95%CI: 6.29, 17.86), age<55 (6.78, 95%CI: 4.79, 9.59) and Child-Pugh class B (23.01, 95%CI:8.07, 65.63) (P = 0.014, 0.046 and 0.033 for interaction, respectively). Trajectories of AFP had the highest relative importance of each parameter to survival, including largest tumor size, intrahepatic lesions number, Child-Pugh class, and baseline AFP. Interpretation AFP trajectories were associated with overall survival for intermediate-stage HCC after TACE. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd.
引用
收藏
页数:10
相关论文
共 37 条
[1]   Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce a-Fetoprotein [J].
Agopian, Vatche G. ;
Harlander-Locke, Michael P. ;
Markovic, Daniela ;
Zarrinpar, Ali ;
Kaldas, Fady M. ;
Cheng, Elaine Y. ;
Yersiz, Hasan ;
Farmer, Douglas G. ;
Hiatt, Jonathan R. ;
Busuttil, Ronald W. .
JAMA SURGERY, 2017, 152 (01) :55-64
[2]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[3]   Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Bruix, Jordi ;
Qin, Shukui ;
Merle, Philippe ;
Granito, Alessandro ;
Huang, Yi-Hsiang ;
Bodoky, Gyrogy ;
Pracht, Marc ;
Yokosuka, Osamu ;
Rosmorduc, Olivier ;
Breder, Valeriy ;
Gerolami, Rene ;
Masi, Gianluca ;
Ross, Paul J. ;
Song, Tianqiang ;
Bronowicki, Jean-Pierre ;
Ollivier-Hourmand, Isabelle ;
Kudo, Masatoshi ;
Cheng, Ann-Lii ;
Llovet, Josep M. ;
Finn, Richard S. ;
LeBerre, Marie-Aude ;
Baumhauer, Annette ;
Meinhardt, Gerold ;
Han, Guohong .
LANCET, 2017, 389 (10064) :56-66
[4]   New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy [J].
Chan, Stephen L. ;
Mo, Frankie K. F. ;
Johnson, Philip J. ;
Hui, Edwin P. ;
Ma, Brigette B. Y. ;
Ho, Wing M. ;
Lam, Kwok C. ;
Chan, Anthony T. C. ;
Mok, Tony S. K. ;
Yeo, Winnie .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) :446-452
[5]   α-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma [J].
Chen, LT ;
Liu, TW ;
Chao, Y ;
Shiah, HS ;
Chang, JY ;
Juang, SH ;
Chen, SC ;
Chuang, TR ;
Chin, YH ;
Whang-Peng, J .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 (03) :217-226
[6]  
European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
[7]   Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma [J].
Gao, Qiang ;
Zhu, Hongwen ;
Dong, Liangqing ;
Shi, Weiwei ;
Chen, Ran ;
Song, Zhijian ;
Huang, Chen ;
Li, Junqiang ;
Dong, Xiaowei ;
Zhou, Yanting ;
Liu, Qian ;
Ma, Lijie ;
Wang, Xiaoying ;
Zhou, Jian ;
Liu, Yansheng ;
Boja, Emily ;
Robles, Ana I. ;
Ma, Weiping ;
Wang, Pei ;
Li, Yize ;
Ding, Li ;
Wen, Bo ;
Zhang, Bing ;
Rodriguez, Henry ;
Gao, Daming ;
Zhou, Hu ;
Fan, Jia .
CELL, 2019, 179 (02) :561-+
[8]   Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma [J].
Halazun, Karim J. ;
Rosenblatt, Russell E. ;
Mehta, Neil ;
Lai, Quirino ;
Hajifathalian, Kaveh ;
Gorgen, Andre ;
Brar, Gagan ;
Sasaki, Kazunari ;
Doyle, Maria B. Majella ;
Tabrizian, Parissa ;
Agopian, Vatche G. ;
Najjar, Marc ;
Ivanics, Tommy ;
Samstein, Benjamin ;
Brown, Robert S., Jr. ;
Emond, Jean C. ;
Yao, Francis ;
Lerut, Jan ;
Rossi, Massimo ;
Mennini, Gianluca ;
Iesari, Samuele ;
Finkenstedt, Armin ;
Schaefer, Benedikt ;
Mittler, Jans ;
Hoppe-Lotichius, Maria ;
Quintini, Cristiano ;
Aucejo, Federico ;
Chapman, William ;
Sapisochin, Gonzalo .
JAMA SURGERY, 2021, 156 (06) :559-567
[9]   Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma [J].
Kelley, Robin Kate ;
Meyer, Tim ;
Rimassa, Lorenza ;
Merle, Philippe ;
Park, Joong-Won ;
Yau, Thomas ;
Chan, Stephen L. ;
Blanc, Jean-Frederic ;
Tam, Vincent C. ;
Tran, Albert ;
Dadduzio, Vincenzo ;
Markby, David W. ;
Kaldate, Rajesh ;
Cheng, Ann-Lii ;
El-Khoueiry, Anthony B. ;
Abou-Alfa, Ghassan K. .
CLINICAL CANCER RESEARCH, 2020, 26 (18) :4795-4804
[10]   Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma [J].
Kim, Beom Kyung ;
Ahn, Sang Hoon ;
Seong, Jin Sil ;
Park, Jun Yong ;
Kim, Do Young ;
Kim, Ja Kyung ;
Lee, Do Youn ;
Lee, Kwang Hoon ;
Han, Kwang-Hyub .
LIVER INTERNATIONAL, 2011, 31 (03) :369-376